Alison HEWAT

Alison is a graduate of Centrale Marseille in chemical engineering, holds a PhD in organometallic chemistry from RWTH Aachen, and a Master’s in Health Law from Paris XI.

She began her career preparing and managing MA dossiers for pain treatment generics within national and mutual recognition procedures. At Axcan (now Allergan), she handled submissions, variations, and renewals for gastro-resistant products, while also managing stability strategies, packaging document control, and reimbursement procedures.

At Helm AG, Alison broadened her expertise by overseeing the generic product lifecycle in decentralized European procedures, coordinating cross-functional teams and subcontractors on technical aspects such as process validation.

In 2012, she joined BD in Grenoble, where she held several strategic roles. As Regulatory Affairs Leader and later Senior Manager, she led an international team supporting the development and registration of injectable combination products for markets including the EU, US, and Asia. In 2022, she was promoted to Associate Director of Regulatory Affairs, continuing to manage complex, multicultural projects in vaccines, biologics, and emergency medicines.

Alison has been recognized with several awards, including the Regulatory Affairs Innovation Award and the XLT Marketing Team Award, and is also a regular international speaker. Today, her leadership and strategic vision make her a key contributor to Atessia’s innovative projects within the CMC team.